How does this framework impact biopharma manufacturers’ current and future drug development plans? How does it change current RWE approaches for generating data on safety and effectiveness? What does this mean for the future of clinical trials?
Join Cardinal Health experts on Tuesday, September 24th at 1:00 PM EST as we analyze case studies and discuss best practices for incorporating RWE as part of the regulatory process.
Bruce Feinberg, DO
Jonathan Kish, PhD, MPH
|Eli Phillips, Jr., PharmD, JD|
Licensed pharmacist and attorney who joined Cardinal Health in June 2014
Todd Phillips, PharmD, RAC